ANGLE (@parsortix) 's Twitter Profile
ANGLE

@parsortix

The leading liquid biopsy company with the first FDA cleared medical device for the capture & harvest of intact CTCs from metastatic breast cancer patient blood

ID: 362669400

linkhttp://ANGLEplc.com calendar_today26-08-2011 19:51:30

1,1K Tweet

14,14K Followers

435 Following

ANGLE (@parsortix) 's Twitter Profile Photo

Using CTCs in cancer research can: - Identify novel drug targets and key drivers of cancer progression - Enable a minimally invasive assessment - Provide the best sample for multi-omic analyses Join #ANGLE at #ASCO May 30 – June 3. Book your 1-1 meeting: angleplc.com/event/american…

Using CTCs in cancer research can:
- Identify novel drug targets and key drivers of cancer progression
- Enable a minimally invasive assessment
- Provide the best sample for multi-omic analyses
Join #ANGLE at #ASCO May 30 – June 3. 

Book your 1-1 meeting:
angleplc.com/event/american…
ANGLE (@parsortix) 's Twitter Profile Photo

Elevate yourĀ CTCĀ research with theĀ CellKeepā„¢ Slide—designed forĀ optimal transfer,Ā morphological integrity, and improvedĀ FISH/IFĀ imaging. Simplify your workflow while enhancing accuracy. #CancerResearch #Biotech

Elevate yourĀ CTCĀ research with theĀ CellKeepā„¢ Slide—designed forĀ optimal transfer,Ā morphological integrity, and improvedĀ FISH/IFĀ imaging. Simplify your workflow while enhancing accuracy.
#CancerResearch #Biotech
ANGLE (@parsortix) 's Twitter Profile Photo

Travelling to Chicago to attend #ASCO2025, May 30 – June 3? Discover our laboratory services for comprehensive liquid biopsy analysis, including CTCs and cfDNA. See how our experts provide the best solution for your clinical trial. Book your 1-1 HERE: angleplc.com/event/american…

Travelling to Chicago to attend #ASCO2025, May 30 – June 3? 

Discover our laboratory services for comprehensive liquid biopsy analysis, including CTCs and cfDNA. See how our experts provide the best solution for your clinical trial. 

Book your 1-1 HERE: angleplc.com/event/american…
ANGLE (@parsortix) 's Twitter Profile Photo

Join our team at #ASCO, May 30 – June 3, to discover CTCs solutions for your lab! ParsortixĀ® technology provides the optimal solution for CTC capture and harvest from whole blood samples, providing critical insights in cancer research. Book your 1-1: angleplc.com/event/american…

Join our team at #ASCO, May 30 – June 3, to discover CTCs solutions for your lab!

ParsortixĀ® technology provides the optimal solution for CTC capture and harvest from whole blood samples, providing critical insights in cancer research.

Book your 1-1:
angleplc.com/event/american…
ANGLE (@parsortix) 's Twitter Profile Photo

ASCO 2025 has started! Our team are onsite and have already learned about many exciting new developments in oncology! Don’t miss your chance to meet with them to discover the benefits of including liquid biopsy and CTC analysis in your cancer research or clinical trials.

ASCO 2025 has started! Our team are onsite and have already learned about many exciting new developments in oncology!

Don’t miss your chance to meet with them to discover the benefits of including liquid biopsy and CTC analysis in your cancer research or clinical trials.
ANGLE (@parsortix) 's Twitter Profile Photo

We are proud to support World Brain Tumour Day 2025, Sunday, 8th June. This commemoration day is an annual tribute to all brain tumour patients and their families. The day is to spread awareness of causes and symptoms associated with brain tumours. braintumourresearch.org/pages/informat…

We are proud to support World Brain Tumour Day 2025, Sunday, 8th June.
This commemoration day is an annual tribute to all brain tumour patients and their families. The day is to spread awareness of causes and symptoms associated with brain tumours.
braintumourresearch.org/pages/informat…
ANGLE (@parsortix) 's Twitter Profile Photo

Next week we'll be attending #EACR2025 in Lisbon! We're excited to join industry leaders and discuss the latest preclinical and translationalĀ cancer research; you can find us at Booth 20. Secure your 1:1 now: angleplc.com/event/annual-c… We look forward to discussing your research!

Next week we'll be attending #EACR2025 in Lisbon!

We're excited to join industry leaders and discuss the latest preclinical and translationalĀ cancer research; you can find us at Booth 20.

Secure your 1:1 now:
angleplc.com/event/annual-c…

We look forward to discussing your research!
ANGLE (@parsortix) 's Twitter Profile Photo

Attend Megan Coates' poster session at #EACR2025 to learn how detecting tumour mutations in liquid biopsies may provide a powerful and non-invasive tool for real-time monitoring of tumour dynamics. Request a 1:1 and join us at Booth 20 angleplc.com/event/annual-c…

Attend Megan Coates' poster session at #EACR2025 to learn how detecting tumour mutations in liquid biopsies may provide a powerful and non-invasive tool for real-time monitoring of tumour dynamics.

Request a 1:1 and join us at Booth 20 angleplc.com/event/annual-c…
ANGLE (@parsortix) 's Twitter Profile Photo

Don’t miss David Greaves' poster session at #EACR2025! Discover the ANGLE PortraitĀ® AR Assay - an immunofluorescence-based assay that allows direct interrogation of AR in blood for minimally invasive monitoring of PCa patients. Request your 1:1 today: angleplc.com/event/annual-c…

Don’t miss David Greaves' poster session at #EACR2025!

Discover the ANGLE PortraitĀ® AR Assay - an immunofluorescence-based assay that allows direct interrogation of AR in blood for minimally invasive monitoring of PCa patients.

Request your 1:1 today:
angleplc.com/event/annual-c…
ANGLE (@parsortix) 's Twitter Profile Photo

Patient advocates offer an important voice in patient care decisions and Stephen Rowley is working to ensure they don’t go unheard. We're honoured to have Steve join our annual company Away Day next week, as he shares his thoughts on the future of cancer patient management.

Patient advocates offer an important voice in patient care decisions and Stephen Rowley is working to ensure they don’t go unheard.

We're honoured to have Steve join our annual company Away Day next week, as he shares his thoughts on the future of cancer patient management.
ANGLE (@parsortix) 's Twitter Profile Photo

The EACR Annual Congress opened its doors today! Don’t miss our posters in the Biomarkers in Tissue and Blood poster session on Tuesday, June 17 from 10.45 – 20.00. Visit Booth 20 to discuss your research. For Research Use Only. Not for Use In Diagnostic Procedures.

The <a href="/EACRnews/">EACR</a>  Annual Congress opened its doors today! Don’t miss our posters in the Biomarkers in Tissue and Blood poster session on Tuesday, June 17 from 10.45 – 20.00. 
Visit Booth 20 to discuss your research.
For Research Use Only. Not for Use In Diagnostic Procedures.
ANGLE (@parsortix) 's Twitter Profile Photo

New posters available! David Greaves and Megan Coates presented their posters during the Biomarkers in Tissue and Blood poster session at EACR2025 yesterday. View the posters in full: angleplc.com/resources/post… For Research Use Only. Not for Use In Diagnostic Procedures.

New posters available!
David Greaves and Megan Coates presented their posters during the Biomarkers in Tissue and Blood poster session at EACR2025 yesterday.

View the posters in full:
angleplc.com/resources/post…

For Research Use Only. Not for Use In Diagnostic Procedures.
ANGLE (@parsortix) 's Twitter Profile Photo

Analysis of circulating tumour cells (CTC) from glioblastoma (GBM) patients enables minimally invasive protein and molecular biomarker analysis and longitudinal monitoring. ANGLE can help you incorporate this powerful tool into your GBM research study. angleplc.com/applications/g…

Analysis of circulating tumour cells (CTC) from glioblastoma (GBM) patients enables minimally invasive protein and molecular biomarker analysis and longitudinal monitoring. ANGLE can help you incorporate this powerful tool into your GBM research study. angleplc.com/applications/g…
ANGLE (@parsortix) 's Twitter Profile Photo

We’re back from #EACR2025 and are energised by the work happening within #CancerResearch. Showing how #LiquidBiopsy is reshaping the way that cancer is understood, tracked, and treated; these conversations reinforce the collective drive behind the potential for patient impact.

We’re back from #EACR2025 and are energised by the work happening within #CancerResearch.

Showing how #LiquidBiopsy is reshaping the way that cancer is understood, tracked, and treated; these conversations reinforce the collective drive behind the potential for patient impact.
ANGLE (@parsortix) 's Twitter Profile Photo

We are excited to welcome Corina Veronica Sasso from #Biomol, our Spanish distributor, to #ANGLE for two days of intensive product training and strengthening our global customer support network. Find your nearest ANGLE supplier: angleplc.com/contact-us/

We are excited to welcome Corina Veronica Sasso from #Biomol, our Spanish distributor, to #ANGLE for two days of intensive product training and strengthening our global customer support network. Find your nearest ANGLE supplier: angleplc.com/contact-us/
ANGLE (@parsortix) 's Twitter Profile Photo

The #ANGLE team attended the #GenomicsEnglandResearchSummit2025 and were blown-away with the Genomics England’s continued mission to secure the UK’s position as the best place to discover, prove, and benefit from genomic innovations. #ANGLEplc #GenomicsEngland #CancerResearch

The #ANGLE team attended the #GenomicsEnglandResearchSummit2025 and were blown-away with the Genomics England’s continued mission to secure the UK’s position as the best place to discover, prove, and benefit from genomic innovations.
#ANGLEplc #GenomicsEngland #CancerResearch
ANGLE (@parsortix) 's Twitter Profile Photo

Repeat tissue biopsies in GBM are often not feasible due to tumour location or patient status. ANGLE's ParsortixĀ® technology enables the capture of CTCs from peripheral blood, offering a repeatable and minimally invasive option for comprehensive, multiomic profiling in GBM.

Repeat tissue biopsies in GBM are often not feasible due to tumour location or patient status. ANGLE's ParsortixĀ® technology enables the capture of CTCs from peripheral blood, offering a repeatable and minimally invasive option for comprehensive, multiomic profiling in GBM.
ANGLE (@parsortix) 's Twitter Profile Photo

The PortraitĀ®+ kit provides advanced immunofluorescent staining of circulating tumour cells (CTCs) including epithelial, mesenchymal, and EMT, from whole blood samples. The PortraitĀ®+ CTC staining kit enables visualisation of CTCs from multiple cancer types.

The PortraitĀ®+ kit provides advanced immunofluorescent staining of circulating tumour cells (CTCs) including epithelial, mesenchymal, and EMT, from whole blood samples. 
The PortraitĀ®+ CTC staining kit enables visualisation of CTCs from multiple cancer types.
ANGLE (@parsortix) 's Twitter Profile Photo

An exciting new study by Professor Nicola Aceto's team at ETH Zurich, Switzerland, published in Nature Genetics identifies circulating tumour cell (CTC) clusters as promising targets to stop the spread of cancer. Read the full publication here: angleplc.com/resources/publ…

An exciting new study by Professor Nicola Aceto's team at ETH Zurich, Switzerland, published in Nature Genetics identifies circulating tumour cell (CTC) clusters as promising targets to stop the spread of cancer. Read the full publication here: angleplc.com/resources/publ…
ANGLE (@parsortix) 's Twitter Profile Photo

Compelling evidence highlights ANGLE’s circulating tumour cell (CTC) enrichment platform, the ParsortixĀ® system, the leading solution for CTC capture in glioblastoma (GBM) — one of the most challenging tumour types for liquid biopsy analysis. Discover why: angleplc.com/applications/g…

Compelling evidence highlights ANGLE’s circulating tumour cell (CTC) enrichment platform, the ParsortixĀ® system, the leading solution for CTC capture in glioblastoma (GBM) — one of the most challenging tumour types for liquid biopsy analysis. Discover why: angleplc.com/applications/g…